R
RevOpsis Therapeutics
Innovative bispecific platform targeting eye diseases to prevent blindness with advanced therapeutic agents
About RevOpsis Therapeutics
RevOpsis Therapeutics is a biotechnology company dedicated to addressing blindness through innovative treatments. Leveraging a proprietary bispecific platform, the company develops fully human, antibody-like proteins designed to target multiple clinically validated biological pathways. This approach aims to improve disease outcomes and extend disease remission for a broad range of eye diseases. RevOpsis Therapeutics primarily serves patients suffering from various eye conditions, operating within the healthcare and biotechnology markets. The business model revolves around the research, development, and commercialization of therapeutic agents, generating revenue through product sales and potential partnerships with other healthcare entities.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Sep 2025 | $0 | — | ExSight Ventures | ↗ |
| DEBT✓Debt | Apr 2024 | $7.5M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for RevOpsis Therapeutics is 160 monthly website visits, down 85.5% over the last three months. RevOpsis Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Draig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment |
Cardiff, United Kingdom | Operational | 44 | $217M | $700M |
Xanadu BioPioneering cystic fibrosis treatment through small molecules and gene editing |
Lower Merion Township, United States | Operational | |||
Solve TherapeuticsTargeted cancer therapies enhancing safety and precision |
San Diego, United States | Operational | |||
35PharmaAdvancing therapeutic biologics to treat cardiopulmonary and metabolic diseases |
Montreal, Canada | Acquired | |||
AviadoBioPrecision gene therapies for neurodegenerative disorders |
London, United Kingdom | Operational | |||
Teitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases |
Aarhus, Denmark | Operational | |||
BioCaptivaNovel liquid biopsy device for cancer diagnostics |
St Andrews, United Kingdom | Operational | |||
MICA BiosystemsBiomagnetic technology for remote-controlled regenerative medicine applications |
Solihull, United Kingdom | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
RevOpsis Therapeutics in the Springfield ecosystem
The RevOpsis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
ExSight Ventures
Other known investors1 additional known investor
University of Colorado
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about RevOpsis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See RevOpsis Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










